Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:acquisitionYear |
2024
|
| gptkbp:CEO |
gptkb:Bill_Meury
|
| gptkbp:clinicalTrialPhase |
Phase 3 (KarXT for schizophrenia)
|
| gptkbp:focusesOn |
gptkb:Alzheimer's_disease
schizophrenia neuropsychiatric disorders |
| gptkbp:foundedIn |
2009
|
| gptkbp:founder |
gptkb:Andrew_Miller
|
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Karuna Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:KarXT
|
| gptkbp:numberOfEmployees |
approximately 200 (2023)
|
| gptkbp:publiclyTraded |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:KRTX
|
| gptkbp:website |
https://www.karunatx.com/
|
| gptkbp:bfsParent |
gptkb:PureTech_Health
|
| gptkbp:bfsLayer |
4
|